Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN
Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ Frost & Sullivan Institute is proud to present Samsung Biologics with the 2022 Enlightened Growth Leadership Award. The Institute believes that all organizations must either create or become part of a solution that addresses threats to humanity. Samsung Biologics has not only demonstrated growth excellence through its strong financial performance in 2021, but also excels as a socially responsible enterprise with a concerted focus on the company's strong ESG and sustainability initiatives. As a response to climate change, Samsung Biologics made progress in reducing Scope 1 and 2 emissions by 32.3% compared to the previous year. To foster collaborative solutions, Samsung Biologics also announced its participation in the Frontier 1.5D initiative to de
/PRNewswire/ Samsung Biologics (KRX: 207940.KS), the world s leading contract development and manufacturing organization, today announced strong financial.
Aerie Pharmaceuticals (NASDAQ:AERI – Get Rating) and Vir Biotechnology (NASDAQ:VIR – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Volatility and Risk Aerie Pharmaceuticals has a beta of 0.39, […]